Postmarketing surveillance for drug safety

被引：0

作者：

Holden, WL ^{[1
]}

Scarazzini, LJ ^{[1
]}

机构：

[1] Aventis, Global Pharmacovigilance & Epidemiol, Bridgewater, NJ USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 76卷 / 05期

关键词：

D O I：

10.1016/j.clpt.2004.07.012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：503 / 503

页数：1

共 50 条

[1] Postmarketing surveillance for drug safety - Reply
Griffin, MR
Stein, CM
Ray, WA
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (05) : 504 - 505
[2] An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
Misu T.
Kortepeter C.M.
Muñoz M.A.
Wu E.
Dal Pan G.J.
Drugs - Real World Outcomes, 2018, 5 (2) : 91 - 99
[3] US FDA enhancing postmarketing drug safety surveillance
Reactions Weekly, 2019, 1780 (1) : 3 - 3
[4] US FDA Enhancing Postmarketing Drug Safety Surveillance
不详
PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 64 - 64
[5] POSTMARKETING DRUG SURVEILLANCE
FELDMANN, EG
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (12) : R1 - R1
[6] POSTMARKETING DRUG SURVEILLANCE
BORDEN, EK
GARDNER, JS
WESTLAND, MM
GARDNER, SD
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 251 (06): : 729 - 729
[7] An Evaluation of Drug-Ineffective Postmarketing Reports in Drug Safety Surveillance
Misu, Takashi
Kortepeter, Cindy
Munoz, Monica
Wu, Eileen
Chung, Haemy
Dal Pan, Gerald J.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 324 - 324
[8] The Landscape of Active Surveillance Systems for Postmarketing Drug Safety Monitoring
Ali, Ayad K.
Meyers, Kristin J.
Huang, Yu-Jing
Salinas, Claudia A.
Li, Hu
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 407 - 407
[9] The Prescription Drug User Fee Act: Active postmarketing drug surveillance and safety
Lyles, A
CLINICAL THERAPEUTICS, 2002, 24 (05) : 800 - 802
[10] POSTMARKETING SURVEILLANCE OF THE SAFETY OF CIMETIDINE
CROMBIE, IK
BRITISH MEDICAL JOURNAL, 1983, 286 (6383): : 2062 - 2062

← 1 2 3 4 5 →